Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Very Good News!

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Dec 16, 2022 5:07pm

333 Views

Post# 35176924

RE:RE:Very Good News!

Thanks for sharing that. It looks like they treated and reached 12 month evaluation for all 157 patients in this phase 3 trial.. They will continue to follow them for 5 years.

enriquesuave wrote:
In comparison we may very well qualify for AA after data on 40-50 patients IMHO. 2023 all the way!

enriquesuave wrote: FDA approves Adstliadrin for NMIBC. They have 4 instillations ( not bad) but 24% CR at 12 months ( I'm not sure if it 12 months or 450 days. They had issues with manufacturing BLA. We will need an NDA much easier and we have way better results IMO. Already 28% CR plus 10% PR including 14 patients who should normally not be counted in analysis out of 29 patients. https://endpts.com/fda-approves-ferrings-new-gene-therapy-for-bladder-cancer/